IONS Ionis Pharmaceuticals, Inc.

+0.15  (0.32%)
Previous Close 46.79
Open 46.54
Price To book 40.58
Market Cap 5.69B
Shares 121,202,000
Volume 612,143
Short Ratio 6.75
Av. Daily Volume 1,859,460

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 interim data released November 2016.
Cardiovascular disease
Phase 1/2 ongoing
Myotonic Dystrophy Type 1 (DM1)
Phase 3 to be completed in 1H 2017.
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2 data released November 2016.
End-stage renal disease
Phase 3 enrolment completed
Volanesorsen - APROACH
Familial chylomicronemia syndrome (FCS)
Phase 2 data released 3Q 2015
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
Type 2 diabetes
Phase 3 initiated November 2015
Partial lipodystrophy rapidly
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
Type 2 diabetes
Phase 3 initiated November 2015
Familial partial lipodystrophy (FPL)
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.

Latest News

  1. Blog Coverage Ionis Pharma Closed on its Collaboration Agreement with Novartis Following Clearance under the Hart-Scott-Rodino Antitrust Improvements Act
  2. 3 Biotechs With Tremendously Promising Pipelines
  3. Ionis and Akcea Close on Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx
  4. IONIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
  5. Ionis Pharmaceuticals (IONS) Sees Hammer Chart Pattern: Time to Buy?
  6. Ionis Pharmaceuticals to Hold 2016 Financial Results Conference Call
  7. Ionis Earns $75 Million from Bayer for Advancing IONIS-FXI Rx and IONIS-FXI-L Rx
  8. Chardan Analyst Suggests An AveXis-Ionis Pair Trade
  9. Novartis’s Recent Developments
  10. Ionis Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology Strategic Collaboration
  11. Vanguard Health Care Fund Gains 5 New Stocks
  12. Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
  13. Biogen Inc Makes Up for Lackluster Revenue Growth
  14. Drug could halt, reverse Alzheimer's-related damage: Washington U researchers
  15. Ionis Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IONS) : January 20, 2017
  16. Ionis Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IONS-US : January 19, 2017
  17. New and Returning Bio-Tech Stock Picks for 2017
  18. Biogen Says Spinraza Drug Did Well In Phase 3 Trial
  19. Is Biogen's Stock Ready to Heat Up After a Forgettable 2016?
  20. Ionis Has High Hopes for Heart Drug Volanesorsen